BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 20538001)

  • 1. Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma.
    Thompson PA; Wertheim BC; Zell JA; Chen WP; McLaren CE; LaFleur BJ; Meyskens FL; Gerner EW
    Gastroenterology; 2010 Sep; 139(3):797-805, 805.e1. PubMed ID: 20538001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention.
    Meyskens FL; Gerner EW; Emerson S; Pelot D; Durbin T; Doyle K; Lagerberg W
    J Natl Cancer Inst; 1998 Aug; 90(16):1212-8. PubMed ID: 9719082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps.
    Meyskens FL; Emerson SS; Pelot D; Meshkinpour H; Shassetz LR; Einspahr J; Alberts DS; Gerner EW
    J Natl Cancer Inst; 1994 Aug; 86(15):1122-30. PubMed ID: 8028034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas.
    Raj KP; Zell JA; Rock CL; McLaren CE; Zoumas-Morse C; Gerner EW; Meyskens FL
    Br J Cancer; 2013 Feb; 108(3):512-8. PubMed ID: 23340449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO)¬†+¬†sulindac for the prevention of sporadic colorectal adenomas.
    Zell JA; Lin BS; Madson N; McLaren CE; Gerner EW; Meyskens FL
    Cancer Causes Control; 2012 Oct; 23(10):1739-44. PubMed ID: 22907422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
    Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
    BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DFMO: targeted risk reduction therapy for colorectal neoplasia.
    Laukaitis CM; Gerner EW
    Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):495-506. PubMed ID: 22122766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas.
    Zell JA; Pelot D; Chen WP; McLaren CE; Gerner EW; Meyskens FL
    Cancer Prev Res (Phila); 2009 Mar; 2(3):209-12. PubMed ID: 19258540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.
    Mackenzie GG; Ouyang N; Xie G; Vrankova K; Huang L; Sun Y; Komninou D; Kopelovich L; Rigas B
    Cancer Prev Res (Phila); 2011 Jul; 4(7):1052-60. PubMed ID: 21464038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer.
    Love RR; Jacoby R; Newton MA; Tutsch KD; Simon K; Pomplun M; Verma AK
    Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):989-92. PubMed ID: 9829706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis.
    Giardiello FM; Casero RA; Hamilton SR; Hylind LM; Trimbath JD; Geiman DE; Judge KR; Hubbard W; Offerhaus GJ; Yang VW
    Gastroenterology; 2004 Feb; 126(2):425-31. PubMed ID: 14762779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of transglutaminase activity by polyamines in the gastrointestinal mucosa of rats.
    Wang JY; Viar MJ; Johnson LR
    Proc Soc Exp Biol Med; 1994 Jan; 205(1):20-8. PubMed ID: 7906881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms.
    Sinicrope FA; Velamala PR; Song LMWK; Viggiano TR; Bruining DH; Rajan E; Gostout CJ; Kraichely RE; Buttar NS; Schroeder KW; Kisiel JB; Larson MV; Sweetser SR; Sedlack RR; Sinicrope SN; Richmond E; Umar A; Della'Zanna G; Noaeill JS; Meyers JP; Foster NR
    Cancer Prev Res (Phila); 2019 Nov; 12(11):821-830. PubMed ID: 31484660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.
    Meyskens FL; McLaren CE; Pelot D; Fujikawa-Brooks S; Carpenter PM; Hawk E; Kelloff G; Lawson MJ; Kidao J; McCracken J; Albers CG; Ahnen DJ; Turgeon DK; Goldschmid S; Lance P; Hagedorn CH; Gillen DL; Gerner EW
    Cancer Prev Res (Phila); 2008 Jun; 1(1):32-8. PubMed ID: 18841250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estradiol control of ornithine decarboxylase mRNA, enzyme activity, and polyamine levels in MCF-7 breast cancer cells: therapeutic implications.
    Thomas T; Thomas TJ
    Breast Cancer Res Treat; 1994 Feb; 29(2):189-201. PubMed ID: 8012036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of polyamine synthesis induces p53 gene expression but not apoptosis.
    Li L; Li J; Rao JN; Li M; Bass BL; Wang JY
    Am J Physiol; 1999 Apr; 276(4):C946-54. PubMed ID: 10199827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyamine contents in rectal and buccal mucosae in humans treated with oral difluoromethylornithine.
    Boyle JO; Meyskens FL; Garewal HS; Gerner EW
    Cancer Epidemiol Biomarkers Prev; 1992; 1(2):131-5. PubMed ID: 1306095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis.
    Ignatenko NA; Besselsen DG; Roy UK; Stringer DE; Blohm-Mangone KA; Padilla-Torres JL; Guillen-R JM; Gerner EW
    Nutr Cancer; 2006; 56(2):172-81. PubMed ID: 17474863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial.
    Hull MA; Sandell AC; Montgomery AA; Logan RF; Clifford GM; Rees CJ; Loadman PM; Whitham D
    Trials; 2013 Jul; 14():237. PubMed ID: 23895505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal polyamine profile in normal and adapting (hypo and hyperplastic) intestine: effects of DFMO treatment.
    Hosomi M; Lirussi F; Stace NH; Vaja S; Murphy GM; Dowling RH
    Gut; 1987; 28 Suppl(Suppl):103-7. PubMed ID: 3121452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.